Spotting the Outliers and New Peaks in MAM Runs Automatically
The webinar on October 11, 2023, at 3:00pm CET demonstrates how Protein Metrics' BYOSPHERE platform leverages unified data processing and interactive dashboards to simplify LC-MS data analysis across vendor platforms, enabling efficient quality attribute monitoring through Fold Change and New Peak Detection to identify impurities and trends in MAM runs.
Protein Metrics BYOSPHERE allows organizations to curate, interrogate, and faithfully share biopharmaceutical analytical information for timely decision making.
In this webinar, we present the power of dashboards for quality attribute analysis and to quickly assess trends and anomalies observed from LC-MS and other data.
Learnings:
- How Byosphere, built on trusted data processing software from Protein Metrics, can simplify processing data from different MS vendor platforms
- How unified data processing makes it easier to compare data within dashboards and how to get the most out of your MAM results with minimal effort
- How Fold Change monitoring and New Peak Detection can help analysts visualize potential impurities present in a test sample compared to a reference
Event Details:
- Date: October 11, 2023
- Time: 3:00pm CET
- Format: Virtual
Related
BioGlyph Luma: Protein Design and Computational Modeling Platform
BioGlyph Luma is a next-generation protein design platform that integrates molecular modeling, production, and characterization into a seamless, traceable workflow, automates data management by converting LC-MS data into actionable insights, and connects with industry-standard tools to accelerate biologic discovery and optimize precision in protein and antibody engineering.
Streamlining Bioprocessing Workflows in Dotmatics Solution
On December 11, 2024, from 9:00 to 10:00 JST, a virtual event will present Dotmatics' integrated solutions for streamlining bioprocessing workflows, featuring discussions on their group strategy in biology and bioprocessing, data collection and analysis using the Luma Scientific Cloud Data Platform, efficient protein and oligonucleotide drug analysis data management with Byosphere, and licensing and utilization tips for Byosphere, with speakers including Dotmatics and ProteinMetrics experts.
LIMS vs ELN: Which is the Best Solution for Your Lab?
The article compares Laboratory Information Management Systems (LIMS) and Electronic Laboratory Notebooks (ELN), highlighting that LIMS are sample- and instrument-centric for standardized analyses while ELNs offer flexible data handling for exploratory research, and suggests that modern unified platforms now combine both systems' capabilities to better support comprehensive lab data management and R&D decision-making.
Affinity Selection-Mass Spectrometry with Kd Analysis Overview
The document explains that Kd, the ligand concentration at which half of a protein's binding sites are occupied, is a crucial measure of binding affinity in drug discovery, and describes how Analytical Studio uses Affinity Selection-Mass Spectrometry (AS-MS) to semi-quantitatively determine apparent Kd values by generating dose response curves from mass spectrometry data, with features including customizable data displays and automated Kd calculations to facilitate efficient analysis and candidate ranking.
From Here to Byosphere Webinar Overview
The webinar "From Here to Byosphere" by Protein Metrics highlights how Lonza, a global biotherapeutic CDMO, addresses the challenges of increasing mass spectrometry data volume and diverse molecule analysis by transitioning from the Byos desktop application to the flexible, vendor-neutral Byosphere software, enabling tailored workflows, improved data processing efficiency, and enhanced analytical control for complex protein biotherapeutics throughout the product lifecycle.
How Biotechs Can Streamline Multi-CRO Collaboration in Early Small Molecule Drug Discovery
A recent survey by C&EN BrandLab reveals that biotechs, facing funding challenges post-COVID, are increasingly outsourcing a broad range of early small molecule drug discovery tasks—beyond synthesis—to multiple CROs, with many engaging over five providers, highlighting a growing trend to optimize R&D by leveraging multi-CRO collaborations despite this area being less studied compared to clinical-phase outsourcing.